CAR-T therapies not cost-effective for diffuse large B-cell lymphoma
For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to ...
Dec 5, 2023
0
1